Debra Phipps
Acute Care · Prattville, ALNPI 1780970038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,131, 3.4 times the $625 reported in 2021. Among acute care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$993
- Pfizer$824
- Novo Nordisk$657
- Lilly USA, LLC$624
- GSK$492
- Neurocrine Biosciences, Inc.$465
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,10599%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $993 |
| Pfizer | 48 | $824 |
| Novo Nordisk | 40 | $657 |
| Lilly USA, LLC | 44 | $624 |
| GSK | 27 | $492 |
| Neurocrine Biosciences, Inc. | 20 | $465 |
| Amgen(2 entities) | 24 | $464 |
| AstraZeneca | 20 | $433 |
| Otsuka America Pharmaceutical, Inc. | 13 | $285 |
| Astellas Pharma US Inc | 8 | $231 |
| Exact Sciences | 13 | $227 |
| Sumitomo Pharma America, Inc. | 13 | $207 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $198 |
| Boehringer Ingelheim | 13 | $191 |
| Abbott | 8 | $167 |
| Shield Therapeutics Inc | 5 | $88 |
| Novartis | 5 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Mylan Specialty L.p. | 3 | $54 |
| Intuitive Surgical | 1 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Lundbeck LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Merck | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$7,199 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $134,181 |
| MounjaroTirzepatide | 82 | $90,452 |
| JanuviaSitagliptin Phosphate | 63 | $72,688 |
| EliquisApixaban | 47 | $48,976 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $39,214 |
| MyrbetriqMirabegron | 38 | $33,147 |
| JardianceEmpagliflozin | 29 | $29,496 |
| EntrestoSacubitril/Valsartan | 17 | $28,541 |
| XareltoRivaroxaban | 28 | $26,129 |
| TrulicityDulaglutide | 20 | $24,529 |
| GemtesaVibegron | 21 | $21,859 |
| LinzessLinaclotide | 24 | $18,615 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,774 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $13,073 |
| TradjentaLinagliptin | 11 | $12,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $657 | $134,181120 claims |
| Lilly USA, LLCMounjaro, Trulicity | $624 | $114,981102 claims |
| MerckJanuvia, Janumet | $14 | $85,76174 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $492 | $66,25695 claims |
| PfizerEliquis | $824 | $48,97647 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $191 | $47,71353 claims |
| Astellas Pharma US IncMyrbetriq | $231 | $33,14738 claims |
| NovartisEntresto | $70 | $28,54117 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $207 | $21,85921 claims |
| AbbVieLinzess, Synthroid | $993 | $20,52146 claims |
| AstraZenecaSymbicort | $433 | $11,04228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.
Other acute care in Prattville
- Paige HarrisMontgomery$465K
- Coretta CollinsBirmingham$77K
- Debra DavisFoley$31K
- Leslie GastonMobile$22K
- Gwendolyn HooperTuscaloosa$16K
- Rachel PrytulaDothan$14K
- Jennifer UmbargerMobile$14K
- April KlarHuntsville$13K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.